Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. On the investigation of non-specific effects of BCG: Interpreting global vaccine data

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Lipidomics and the quest for brainy lipids

    Research output: Contribution to journalComment/debateResearchpeer-review

  • D S Courvoisier
  • D Alpizar-Rodriguez
  • J E Gottenberg
  • M V Hernandez
  • F Iannone
  • E Lie
  • M J Santos
  • K Pavelka
  • C Turesson
  • X Mariette
  • D Choquette
  • Merete Lund Hetland
  • A Finckh
View graph of relations

BACKGROUND: Response to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) is often heterogeneous. We aimed to identify types of disease activity trajectories following the initiation of a new biologic DMARD (bDMARD).

METHODS: Pooled analysis of nine national registries of patients with diagnosis of RA, who initiated Abatacept and had at least two measures of disease activity (DAS28). We used growth mixture models to identify groups of patients with similar courses of treatment response, and examined these patients' characteristics and effectiveness outcomes.

FINDINGS: We identified three types of treatment response trajectories: 'gradual responders' (GR; 3576 patients, 91·7%) had a baseline mean DAS28 of 4·1 and progressive improvement over time; 'rapid responders' (RR; 219 patients, 5·6%) had higher baseline DAS28 and rapid improvement in disease activity; 'inadequate responders' (IR; 103 patients, 2·6%) had high DAS28 at baseline (5·1) and progressive worsening in disease activity. They were similar in baseline characteristics. Drug discontinuation for ineffectiveness was shorter among inadequate responders (p=0.03), and EULAR good or moderate responses at 1year was much higher among 'rapid responders' (p<0.001).

INTERPRETATION: Clinical information and baseline clinical characteristics do not allow a reliable prediction of which trajectory the patients will follow after bDMARD initiation.

Original languageEnglish
JournalEBioMedicine
Volume11
Pages (from-to)302-6
Number of pages5
DOIs
Publication statusPublished - Sep 2016

    Research areas

  • Antirheumatic Agents, Arthritis, Rheumatoid, Biological Factors, Biomarkers, Comorbidity, Disease Progression, Female, Follow-Up Studies, Humans, Male, Severity of Illness Index, Treatment Outcome, Journal Article, Multicenter Study

ID: 49915089